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Introduction
Hydrogen sulfide (dihydrogen sulfide, H2S) is a well known and
pungent toxic gas and its toxicology as an environmental pol-
lutant has been extensively studied [1]. Since it was first 
discovered to be synthesized in human tissues a decade ago, it
has attracted substantial interest. Studies in animals have
shown H2S to be involved in several physiological and patho-
physiological processes as diverse as learning and memory,
chronic inflammation and the regulation of blood pressure. It
will not have escaped the reader’s attention that these
processes are also tightly regulated by the much better under-
stood gasesous mediator, nitric oxide. The similarity in physio-
logical and pathophysiological effects between nitric oxide and
H2S has led to speculation about the existence of cellular
‘cross-talk’ between the two gases and the enzymes responsi-
ble for their synthesis.
It should be noted here that although the words sulfur and 
sulphur are widespread in the scientific literature, predominantly
from United States and UK/ UK-Commonwealth based researchers,
respectively, an etymological basis for the spelling of sulphur is
lacking. Sulfur is Latin and not Greek (the Greek for sulfur 
being thion) although both terms continue to be used interchange-
ably. However, it should be noted that the International Union of
Pure and Applied Chemistry (IUPAC) applied the spelling of ‘sulfur’
in 1990 [2]. This was subsequently adopted by the nomenclature
committee of the Royal Society of Chemistry (UK) in 1992 [3]. As
such and to avoid confusion, we refer to H2S as hydrogen sulfide.
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Abstract
Hydrogen sulfide (H2S) is a well known and pungent toxic gas that has recently been shown to be synthesised in man from the amino
acids cystathionine, homocysteine and cysteine by at least two distinct enzymes; cystathionine--lyase and cystathionine--synthase.
In the past few years, H2S has emerged as a novel and increasingly important mediator in the cardiovascular system but delineating the
precise physiology and pathophysiology of H2S is proving to be complex and difficult to unravel with disparate findings reported with
cell types, tissue types and animal species reported. Therefore, in this review we summarize the mechanisms by which H2S has been
proposed to regulate blood pressure and cardiac function, discuss the mechanistic discrepancies reported in the literature as well as the
therapeutic potential of H2S. We also examine the methods of H2S detection in biological fluids, processes for H2S removal and discuss
the reported blood levels of H2S in man and animal models of cardiovascular pathology. We also highlight the complex interaction of
H2S with nitric oxide in regulating cardiovascular function in health and disease.
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Reactive nitrogen species (RNS) in the
heart and vasculature
Nitric oxide and peroxynitrite (ONOO) are RNS formed in vivo
(extensively reviewed in [4]). Nitric oxide is a free radical gas syn-
thesized enzymatically from the amino acid L-arginine in a number
of tissues using the three isoforms of nitric oxide synthase (NOS).
Classically, NOS1 and NOS-3 are constitutively expressed and require
Ca2 calmodulin to produce low nM quantities of nitric oxide over
short periods of time. NOS2 is an inducible Ca2-independent iso-
form and synthesizes high M concentrations of nitric oxide over a
period of hours. Nitric oxide is important in the endothelium-
dependent regulation of blood flow and pressure, inhibiting the 
activation of blood platelets, neurotransmission and memory 
(long-term potentiation; LTP). Nitric oxide is also involved with
host-defence and the inflammatory cascade (exhaustively reviewed
in [4]). Since the half-life of nitric oxide at physiological pH is 5s,
its formation in vivo can be quantitated by the measurement of its
stable oxidation products, nitrite (NO2) and nitrate (NO3) and
from the S-nitrosation of free or protein thiols  (S-nitrosothiols) [4]. 
The roles of nitric oxide and ONOO in the cardiovascular sys-
tem have been exhaustively studied and reviewed in great detail
elsewhere [4, 7]. Briefly, nitric oxide, through the activation of the
Ca2/calmodulin-dependent enzymes NOS1 and NOS3 maintains
cardiac function and vascular patency through direct endothelial-
dependent interaction with soluble guanylate cylcase resulting in
cGMP accumulation, intracellular protein phosphorylation and
vasorelaxation. In conditions such as sepsis, shock or inflamma-
tion, a third isoform, NOS2 is induced resulting in high concentra-
tions of nitric oxide being synthesized and potentially lethal
hypotension. Administration of NOS2 inhibitors effectively attenu-
ate this hypotension in animal models. In otherwise healthy indi-
viduals or animals, the administration of NOS3 or more recently
NOS1 [8] inhibitors alone can increase blood pressure clearly
demonstrating a role for nitric oxide in regulating blood pressure
homeostasis under physiological conditions. Similarly, nitric oxide
donating drugs exert potent hypotensive actions [9, 10].
In the vasculature, ONOO formation through substantially
elevated nitric oxide synthesis can lead to endothelial lipid perox-
idation, oxidation, nitration and inactivation of Ca2-dependent
vascular smooth muscle cell ATPases. ONOO-mediated oxida-
tion of low-density lipoprotein also leads to the activation of
macrophage scavenge receptor to precipitate atherosclerosis as
well as directly induce smooth muscle and endothelial cell death.
Since this will ultimately lead to impaired vascular response, the
physiological removal of ONOO by antioxidants, decomposition
catalysts [4] or thiols (perhaps including hydrogen sulfide [11]) is
considered beneficial in maintaining a healthy vasculature.
H2S biosynthesis
H2S is rapidly emerging as an important gaseous mediator in the
vasculature. In sharp contrast to nitric oxide, and as one would
expect from an emerging field of research, its vascular effects, its
mechanism of action as well as the processes controlling the regu-
lation of its synthesis are poorly understood. As with nitric oxide,
H2S is a highly lipophilic molecule and freely penetrates cells of all
types. Whether or not H2S and nitric oxide exert their effects in vivo
independently or in tandem is currently not known but a growing
body of literature is highly suggestive of H2S involvement in the reg-
ulation of nitric oxide mediated signalling events and/or vice versa.
The bulk of endogenous H2S synthesis in mammalian tissues
appears to be from the pyridoxal-5-phosphate-dependent
enzymes cystathionine--lyase (CSE; E.C. 4.4.1.1) and cystathion-
ine--synthase (CBS; E.C. 4.2.1.22) and by analogy with NOS use
amino acids as substrates; in this case cystathionine, cysteine and
homocysteine (summarized in Fig. 1). H2S may also be formed 
in vivo from the enzymatic desulfuration of -mercaptopyruvate
derived from cysteine transamination [12] although it is currently
uncertain how this pathway contributes to the levels of H2S
reported in mammalian tissues (see below). In should be noted at
this point that in aqueous solution H2S is weakly acidic (pKa at
37	C, 6.76) and dissociates to form two dissociation states; the
hydrosulfide anion (HS), pKa 7.04 and sulfide anion (S2), pKa
11.96 according to the following sequential reactions
H2S  HS  H S2  2H
As such, at physiological pH of 7.4 approximately 18.5% of the
total sulfide exists as the undissociated acid and 81.5% as the
HS anion [13]. Therefore, since it is currently not known whether
the biological effects of H2S are mediated directly by H2S itself or
derived species that will also exist at pH 7.4 (such as S2 or HS),
we prudently use the term H2S in this review to reflect the sum of
these species present at physiological pH.
The human gene for CSE is located on chromosome 1 (1p31.1)
and two possible splice variants of CSE mRNA have been character-
ized although their precise function in H2S synthesis are unknown.
CSE expression is induced in liver, kidney and lung by pro-
inflammatory mediators such as lipopolysaccharide [14] and also in
animal models of type I diabetes mellitus [15] and pancreatitis [16]
although the precise molecular pathways for the induced expression
of CSE and activity remain elusive. Similarly, the human CBS gene
is located on chromosome 21 (21q22.3) [17] and encodes several
mRNA [18] but the function of these mRNA isoforms in terms of
H2S synthesis are not known. However, it has been suggested that
the heme component of CBS functions as a cellular redox sensor
[19] perhaps increasing H2S generation in response to intracellular
oxidant load. Interestingly, CBS is allosterically regulated by 
S-adenosylmethionine [20] and stimulation of CBS activity
increases glutathione (GSH) synthesis by promoting cellular 
cysteine uptake and accompanying increased -glutamylcysteine
synthetase activity [21, 22] suggesting a role for CBS (and perhaps
H2S) in addressing intracellular redox imbalances due to increased
oxidant load. In agreement, H2S or species derived from it at physio -
logical pH, react with several cytotoxic oxidant species such as
hypochlorite [23], peroxynitrite [10], hydrogen peroxide, O2–
[24, 25] and nitric oxide [26] and prevent cell death induced by
these oxidants suggesting a cytoprotective function for H2S.
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As with the various isoforms of NOS, CSE and CBS are widely
expressed in human tissues and cells although a degree of tissue
specificity is apparent. CBS is highly expressed in neuronal tissue,
in particular in cerebellar Purkinje and hippocampal neurons. In
contrast, CSE activity is most notable in blood vessels and periph-
eral tissues [27]. The liver of several species, including human
beings, contain high levels of CSE and CBS expression and activity.
Although there has been considerable interest in CSE and CBS over
several decades due to their role in the trans-sulfuration pathway
and homocysteine metabolism, very little is known about the pre-
cise molecular pathways for H2S synthesis from these enzymes. In
neuronal tissue, CBS activity appears Ca2/calmodulin-dependent
suggesting that short-term control H2S synthesis may be achieved
by Ca2 influx following neuronal depolarization [28] in a similar
process to the synthesis of nitric oxide from the cal-
cium/calmodulin-dependent NOS. The high endogenous concentra-
tions of H2S measured in human, rat and bovine brain (between 50
and 160 m) has led to the suggestion that like nitric oxide, H2S
may function as an endogenous neuromodulator [29, 30].
H2S measurement, catabolism and removal
At present there are no known specific and reliable stable end
products of H2S biosynthesis in the same way that NO2/NO3
function as a robust index of NOS activity in vivo. The majority of
studies which have evaluated serum or plasma levels of H2S have
used a spectrophotometric approach based around methylene
blue. This assay involves the ‘fixing’ or ‘trapping’ of aqueous sul-
fide in biological samples with zinc acetate to prevent unnecessary
loss of H2S through volatilization or through aerial oxidation
resulting in the formation of stable zinc sulfide [31]. Upon subse-
quent acidification, H2S is released and in the presence of N,N-
dimethyl-p-phenylenediamine (DMPD) and of small quantities of
ferric ions, the heterocyclic thiazine dye methylene blue produced
can be readily measured using standard laboratory spectropho-
tometers at 670 nm (Fig. 2) [31] or analysed by high-performance
liquid chromatography (see Table 1 for comparison of methods
and levels of H2S reported in mammalian serum and plasma). It is
possible that this spectrophotometric assay measures the sum of
Fig. 1 Major Pathways of H2S synthesis in
vivo. H2S is synthesized from the amino acids
L-cysteine and L-cystathionine by one of two
enzymes (depending on cell type), cystathion-
ine--synthase (CBS) and cystathionine--
lyase (CSE). Aminooxyacetate and propargyl-
glycine (PAG) are commonly used inhibitors of
CBS and CSE activity, respectively. The most
prominent source of H2S in the vasculature is
CSE. Removal of H2S is thought to occur via
oxidation to sulfate (SO42), sulfite (SO32–)
and thiosulfate (S2O32), scavenging by
methemoglobin (MetHb) or methylation by
enzymes such as thiolmethyltransferase
(TMT) and rhodanese to form methanethiol
(CH4S) and dimethylsulfide (CH3SCH3).
Fig. 2 Methylene blue assay for H2S in biological fluids. This is the most simple and widely used assay for determining H2S levels in body fluids. Using
this and other methods (see Table 1), healthy human blood has been found to contain ~30-60 M of H2S. H2S levels are reduced in hypertension and
increased during endotoxic or haemorrhagic shock. Modified from [31].
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Species Model Method of H2S
detection
Fluid H2S level reported Comment References
Male Sprague-
Dawley rats
Myocardial injury
induced by homo-
cysteine treatment
Commercial 
sulfide-sensitive
electrode
Plasma Control rats, ~30
µM* Homocysteine
treatment, ~50
µM*
Homocysteine is a substrate for CSE.
H2S prevented myocardial injury. CSE
expression and activity were lowered
by high concentrations of H2O2
(0.1–10mM)
[34]
Rats – species not
specified
Isoproterenol-
induced myocardial
injury
Zinc acetate / N,N-
dimethyl-
p-phenylenedi-
amine (DMPD)
Plasma Control rats, 
~65 µM*
Isoprotenerol
treated rats, 
~18 µM*
CSE involved in mediating cardiac
contraction. Treatment of rats with iso-
proterenol and NaHS significantly low-
ered CPK and LDH release from
myocardial tissue, lowered the levels
of lipid peroxidation products and pre-
served left ventricular function. NaHS
increased survival, induced capillary
dilatation and reduced leucocyte infil-
tration into myocardial tissue. Part of
the mechanism for these observations
may include H2S-mediated ‘scaveng-
ing’ of H2O2 and O2.
[25]
Male Sprague-
Dawley rats
Endotoxemia
induced by bacter-
ial lipopolysaccha-
ride from E. Coli
Zinc acetate /
DMPD
Plasma Control rats, ~26
µM* LPS treated
rats, ~45 µM*
LPS increase plasma PGE2 levels; an
effect decreased by the H2S-releasing
drug S-diclofenac LPS increased
plasma NO2 levels; decreased by 
S-diclofenac suggesting H2S–nitric
oxide cross-talk
[113]
Male Sprague-
Dawley rats, WKY
rats,
Spontaneously
hypertensive rats
(SHR)
Development of a
novel slow releas-
ing H2S donor
(GYY4137);
Hypertension:
induced by 
L-NAME induced
hypertension, nor-
motensive rats and
SHR
Zinc acetate /
DMPD
Plasma Baseline levels of
~35 µM* rose to
~80 µM* 90 min
after i.v. or i.p.
administration of
H2S donor.
First demonstration of the biphasic
effects of H2S on cardiac function.
Rapid release of H2S by NaHS reduced
cardiac contractility (left ventricular
diastolic pressure) by 42% and heart
rate by 53%. In contrast, the slow and
sustained release of H2S via GYY4137
had no effect on cardiac contractility
or heart rate. NaHS increased mean
arterial blood pressure in L-NAME
treated rats whereas GYY4137 pre-
vented L-NAME-induced hypertension.
Furthermore GYY4137 markedly
reduced systolic pressure in SHR but
not WKY rats.
[79]
Male Sprague-
Dawley rats
Type I diabetes
induced by strepto-
zotocin (STZ)
Zinc acetate /
DMPD
Plasma Control rats, ~40
µM STZ treated
rats, ~38 µM 
Insulin treatment significantly elevated
plasma H2S levels. STZ elevated liver,
kidney and pancreas CSE and CBS
expression and activity. STZ is a nitric
oxide donating molecule and the
decreased plasma levels of H2S after
STZ treatment could reflect consump-
tion of H2S by nitric oxide and / or
derived intermediates
[15]
Table 1 Comparison of plasma and serum levels of H2S determined by several commonly used techniques: relevance to the cardiovascular system
Continued
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Table 1 Continued
Continued
Species Model Method of H2S
detection
Fluid H2S level reported Comment References
Male Sprague-
Dawley rats
High blood-flow
induced pulmonary
hypertension
induced by abdom-
inal aorta-inferior
cava vein shunt
Zinc acetate /
DMPD
Plasma Control rats, 50.9

 3.9 µM
Pulmonary hyper-
tensive rats, 36.4

 2.6 µM 
Shunt decreased CSE mRNA expression in
lung CSE mRNA localized in smooth mus-
cle cells on small pulmonary muscular
arteries with minimal expression in
endothelial cells
[110]
Male Sprague-
Dawley rats
High blood flow
induced pulmonary
hypertension
induced by abdom-
inal aorta-inferior
cava vein shunt
Zinc acetate /
DMPD
Plasma Control rats, 50.83

 4.01 µM Shut,
36.42 
 3.12 µM 
Shunting decreased CSE mRNA expression
in medial and small pulmonary arteries and
rate of H2S synthesis in lung tissue
[111]
Male WKY and
spontaneous
hypertensive (SHR)
rats
Hypertension Zinc acetate /
DMPD
Plasma WKY rats 48 
 13
µM SHR rats 20 

9 µM 
PAG treatment decreased H2S levels in
WKY (to 21 
 7 µM) and SHR (to 12 

10 µM) and also increased the expression
of CSE in aorta in WKY and SHR suggest-
ing H2S involvement in regulation of blood
pressure
[61]
Male Sprague-
Dawley rats
Haemorrhagic
shock (blood with-
drawl, 9-10ml over
an hour in 2 min
periods)
Zinc acetate /
DMPD
Plasma Prior to blood
withdrawl, 28.9 

1.4 µM 60 min
after blood with-
drawl, 37.5 
 1.3
µM
PAG or -cyanoalanine injected either pro-
phylactically or therapeutically, inhibited
the increase in plasma H2S and drop in
mean arterial blood pressure. This
response was not inhibited by gliben-
clamide (KATP channel antagonist). Blood
withdrawl increased liver CSE mRNA
expression
[62]
Wistar rats Hypoxic pulmonary
hypertension
(HPH)
Zinc acetate /
DMPD
Plasma Control rats, 301.6

 32.41 µM HPH,
92.2 
 22.1 µM
NaHS increased lung CSE expression; lev-
els of control rats approximately 10 fold
higher than the reported findings of others
with the same species of rat (see below).
Nevertheless, HPH induced a significant
decrease in plasma H2S. 
[43]
Male Wistar rats Myocardial infarc-
tion; ligation of left
anterior descend-
ing artery from its
origin between the
pulmonary artery
conus and the left
atrium
Zinc acetate /
DMPD
Plasma Control rats, 38.2

 2.07 µM 48 hrs
after MI induction,
59.2 
 7.16 µM
PAG treatment reduced plasma H2S levels
to 39.2 
 5.02 µM whereas treatment with
the H2S donor, NaHS, significantly
increased plasma H2S levels to 92.2 

12.40 µM. MI and PAG treatment
decreased CSE mRNA expression. PAG
treatment reduced myocardial oedema and
inflammatory cell infiltrate. CSE immunore-
activity detected in infarct area as well as
in the endothelium of small vessels of area
at-risk. In contrast, CSE was not detected
in cardiomyocytes under these experimen-
tal conditions.
[70]
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Table 1 Continued
Species Model Method of H2S
detection
Fluid H2S level reported Comment References
Male Wistar rats Hypoxic pulmonary
hypertension
Zinc acetate /
DMPD
Plasma Control group,
299.6 
 12.4 µM
Hypoxia, 187.2 

13.1 µM
NaHS increased lung CSE expression;
levels of control rats approximately 10
fold higher than the reported findings of
others with the same species of rat .
Administration of NaHS to hypoxia
treated rats increased plasma H2S levels
to 309.2 
 13.6 µM Potential antioxi-
dant action of H2S: Hypoxia decreased
plasma antioxidant enzyme superoxide
dismutase (SOD), increased levels of
oxidized glutathione (GSSG) and lipid
peroxidation markers (malondialde-
hyde); these effects were reversed by
NaHS administration.
[114]
Male Sprague-
Dawley rats
Cardiac ischemia
reperfusion; occlu-
sion of left anterior
descending coro-
nary artery
Zinc acetate /
DMPD
Plasma Control group,
58.28 
 7.86 µM
Ischemia-reperfu-
sion group 30.32

 5.26 µM
NaHS decreased infarct size and
improved haemodynamics (increased
left ventricular diastolic pressure)
Suggested mechanism for cardioprotec-
tion via down-regulation of c-fos
expression in myocardium. 
[115]
Male Sprague-
Dawley rats
Commercial 
sulfide-sensitive
electrode
Plasma Healthy rats, 45.6

 10.59 µM
[109]
Lobund-Wistar
(LW) rats Harlan-
Sprague-Dawley
(HSD) rats C57
Black/6 (C57) mice
Method compari-
son study
Polarographic
H2S sensor and
Ion-selective
electrode Zinc
acetate / DMPD
Plasma H2S was not
detected in LW or
HSD rats or C57
mice. H2S was not
detected in LW rats
but 4.3 
 0.5 µM
detected in HSD rat
plasma.
This study also shows the rapid
removal, metabolism or sequestration of
H2S added to vertebrate plasma; half
time of decay of 10 µM Na2S added to
plasma at 37	C, 13.0 
 0.2 sec.
[38]
Male Swiss albino
mice
Septic shock
(induced by LPS)
Zinc acetate /
DMPD
Plasma Untreated animals,
~32M* LPS 4 hrs,
~40M LPS 20 hrs,
~65M
LPS induced liver and kidney CSE
expression and activity was inhibited
by PAG. H2S levels correlated with
myeloperoxidase expression and 
activity.
[14]
Male Balb/C mice Acute pancreatitis
induced by
caerulein 
Zinc acetate /
DMPD
Plasma Control mice, 22.5

 1.9 µM
Caerulein treat-
ment, 31.1 
 3.3
µM 
Pancreatitis-induced CSE expression
elevated plasma H2S levels. PAG treat-
ment lowered plasma H2S levels, levels
pancreatic amylase and myeloperoxi-
dase activity, inhibited acinar cell death
and lung injury.
[116]
Plasma Control mice, ~30
µM* Caerulein
treatment, ~35
µM*
[117]
Continued
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Table 1 Continued
Continued
Species Model Method of H2S
detection
Fluid H2S level reported Comment References
Male Swiss
albino mice
Cecal ligation and
puncture-induced
sepsis (CLP)
Zinc acetate /
DMPD
Plasma Normal, ~10 µM* Sham,
~13 µM* CLP, 20 µM*
Sepsis-induced CSE expression and
elevated plasma H2S levels. Plasma
H2S levels were significantly lowered
after prophylactic or therapeutic
treatment with PAG.
[118]
Female NOR/Ltj
and female
NOD/Ljt mice
Non-obese diabetic
mouse model and
controls
Zinc acetate /
DMPD
Plsama Control mice (NOR/Ljt),
~60 µM* NOD mice
stage I, ~60 µM* stage
II, ~33 µM* stage III,
~27 µM*
Plasma levels of H2S decreased
markedly as disease progressed. 
L-cysteine stimulated synthesis of
H2S and vasorelaxant effect in aortic
tissue were significantly decreased
with increasing disease progression.
[119]
Male C57BL/6J
mice
Genetic knock-out
studies; Wild-type
(CSE/), CSE/
and CSE/
Commerical 
sulfide 
ion-selective
electrode 
Serum CSE/ mice ~40 µM*
CSE/ mice ~31 µM*
CSE/ mice ~18 µM*
CSE/ mice had higher systolic blood
pressure than CSE/ mice; CSE/
mice had higher systolic blood pressure
than CSE/ mice. CSE/ more sen-
sitive to H2S-induced vasodilatation
than CSE/. 
[55]
Human Chronic obstructive
pulmonary disease
(COPD); 27
patients with acute
exacerbation of
COPD (AECOPD),
37 patients with
stable COPD 
Commercial 
sulfide-sensitive
electrode
Serum: healthy volunteers; aged
71-80yrs, 35.7 
 1.2 µM
aged 61-70yrs, 34.0 

0.9 µM aged 50-60yrs,
36.1 
 1.1 µM No signif-
icant difference between
healthy and AECOPD
(~35 µM*) but elevated
to in stable COPD
patients (non-smokers,
51.1 
 3.0 µM; smokers
49.8 
 3.8 µM)
Smoking significantly lowered plasma
levels of H2S in healthy controls and
AECOPD patients. High levels of nitric
oxide (measured as total
nitrite/nitrate) correlated to higher H2S
levels. H2S levels also correlated with
stage of lung obstruction with COPD*
(Stage I, ~72 µM; Stage II, ~50 µM;
Stage III, ~40 µM; Stage IV, ~48 µM)
H2S levels negatively correlated with
sputal neutrophil count and positively
with lung function (predicted FEV1).
[33]
Human Chronic obstructive
pulmonary disease
(COPD); 18
patients before and
after theophylline
treatment
Commercial 
sulfide-sensitive
electrode
Serum COPD 30-100 µM*
Serum levels unaffected
by theophylline treat-
ment. 
H2S levels positively correlated with
percentage of predicted FEV1, sputum
macrophage levels but negatively cor-
related with sputum neutrophil count.
Sputum levels of H2S were equivalent
to levels of NO2. 
[120]
Human 40 patients with
coronary heart dis-
ease (CHD), 17
angiographically
normal patients
Commercial 
sulfide-sensitive 
electrode
Plasma: Normal controls, 51.7 

11.9 µM CHD, 26.1 

14.2 µM Single vessel
CHD, 33.0 
 15.0 µM
Double vessel CHD, 16.9

 7.9 µM Multi-vessel
CHD, 18.4 
 7.8 µM
Unstable angina, 23.6 

14.4 µM Acute myocar-
dial infarction, 19.9 
 7.5
µM Stable angina, 38.4 

14.5 µM CHD with coro-
nary artery occlusion, 
Patients with CHD had significantly
lower H2S levels compared to angio-
graphically normal controls. The num-
ber of affected vessels correlated with
a decrease in H2S levels suggesting
decreased H2S levels correlate with
disease severity but could also reflect
either H2S consumption by vascular
oxidants. Plasma levels were also sig-
nificantly negatively correlated to
blood glucose levels and significantly
lower in smokers compared to non-
smokers.
[60]
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Species Model Method of H2S
detection
Fluid H2S level reported Comment References
Human Essential hyperten-
sion in children
Ionic conductance
meter/sulfide 
specific detector
Plasma Control group 65.7

 5.5 µM (mean
age 10.5 
 0.73)
Hypertensive chil-
dren (mean age
10.48 
 3.2yrs),
51.9 
 6.0 µM
High plasma levels of H2S correlated
to low homocysteine concentrations.
Hypertensive children had a lower
H2S: homocysteine ratio compared to
the control group (5.8 
 2.9 cf. 11.6

 3.3). Higher systolic pressure was
associated with a lower plasma
H2S:homocysteine ratio
[95]
Human Healthy controls Gas chromatogra-
phy-mass spec-
trometry with
pentafluorobenzyl
bromide dramatiza-
tion
Whole
frozen
blood
35–80 µM Method evaluation paper. [35]
Human Healthy volunteers Microdistillation
and ion chro-
matography
Plasma Levels differed with
varying dietary
meat intake Meat
free, 42 
 15 µM
240 g meat, 47  

12 µM 420 g meat,
25 
 0.8 µM
This study also directly compared the
methylene blue assay with this chro-
matographic technique and found the
levels obtained in both systems to be
comparable
[36]
Human Healthy volunteers
and septic shock
patients
Zinc acetate /
DMPD
Plasma Age and sex
matched healthy
controls, 43.8 

5.1 M Septic
shock, 150.5 

43.7 M
[14]
Table 1 Continued
*Estimated by the authors from published figures. 
H2S-derived species such as HS and S2 that exist at physiolog-
ical pH rather than H2S itself.
However, the majority of the reported studies been useful in
generating a substantial amount of data for researchers to ‘bench-
mark’ their results and clearly highlight the emerging importance
of H2S and closely related species in the cardiovascular system.
Levels of H2S in the plasma measured using this spectrophoto-
metric assay are generally comparable to other approaches (see
Table 1). For example, Chen et al. [33] utilized a sulfide-selective
electrode and detected serum H2S levels in man of 37.9 
 0.9 M
(healthy controls) cf. 33.0 
 0.7 M (smokers) and 51.1 
 3.0
M (chronic obstructive pulmonary disease [COPD] patients).
Using a similar electrochemical method Chang et al. [34] reported
plasma H2S levels in rat of 30–50 M. Furthermore, the analysis
of human plasma by more laborious analytical techniques such as
gas chromatography-mass spectrometry with pentafluorobenzyl
bromide dramatization or microdistillation with ion chromatrgra-
phy revealed H2S levels of 35–80 M [35] and 25–50 M [36],
respectively. We recently reported comparable serum levels of H2S
in healthy human volunteers using the methylene blue spec-
trophotometric assay and found mean serum levels (
S.D.) of
43.8 
 5 M which were increased markedly (up to 200 M in
one case) during septic shock [14]. As such, the methylene blue
based spectrophotometric assay appears to be convenient, rela-
tively robust and at least comparable to other techniques for the
measurement of plasma H2S (‘free’ H2S, HS or S2).
However, it is prudent to note that while the majority of labora-
tories report plasma H2S in the region of 25–80 M it is important
to note here that a few laboratories have reported markedly differ-
ent findings using the same analytical techniques. For example,
Chenyu et al. [37] have reported levels of in excess of 300 M in
plasma from healthy rats whereas others [38, 39] have suggested
that the actual level of H2S in plasma was beyond the limit of
detection for the methylene blue assay and electrochemical detec-
tors (Table 1). Indeed, using rat tissue homogenates and head
space gas chromatography Furne et al. [39] failed to detect tissue
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release of H2S from the tissues into the head space after supple-
menting tissues with L-cysteine. These important studies do not
necessarily contradict the majority of the reported findings in the
literature (see Table 1) as they would suggest that H2S is
sequestered or carried in plasma and tissues rather than released
as ‘free’ H2S. Indeed, it is intriguing to note here that when solu-
tions of H2S or the commonly used sulfide salt donors (Na2S and
NaHS) are prepared in the laboratory at concentrations reported in
plasma, the solutions are characteristically pungent. However,
blood, plasma, serum or tissue homogenates, while containing
H2S (Table 1) do not smell, further suggesting that the widely used
assays could measure a form of bound or sequestered H2S rather
than ‘free’ H2S.
Whatever the absolute level of H2S in plasma, it is likely that
any reported plasma levels could represent an underestimate of
the true extent of H2S synthesis as pathways for H2S removal exist
(summarized in Fig. 1) although it is uncertain how rapid this
process occurs in the vasculature. The half-life of H2S in mam-
malian plasma has been estimated at 30 min. although the
mechanism for this has not been identified [38]. A direct reaction
with methemoglobin forming sulfhemoglobin has been suggested
and it is possible that sulfhemoglobin could act as a ‘sink’ for cir-
culating H2S as it releases H2S upon reduction. Intracellular path-
ways for H2S removal also exist. In cells, H2S is rapidly oxidized
to thiosulfate (S2O32) by mitochondria and subsequently con-
verted to sulfite (SO32) and the major and stable product, sulfate
(SO42) [40, 41]. Unfortunately, SO42 cannot be used as a 
‘bio-marker’ of endogenous H2S production since it can be derived
from the direct oxidation of cysteine by cysteine dioxygenase 
(E.C. 1.13.11.20) and oxidation of SO32 by sulfite oxidase 
(E.C. 1.8.3.1) [42].
Urinary and blood S2O32 has been used as a marker of envi-
ronmental H2S inhalation [43, 44] and elevated urinary S2O32
has been measured in Down syndrome patients [45] with the sug-
gestion that these reflected an overproduction of H2S in Down
syndrome patients although blood S2O32 levels were not deter-
mined in this study. However, S2O32 may not be completely reli-
able as an index of H2S since S2O32 levels in blood without
detection in urine have also been observed after industrial H2S
poisoning [46, 47] and urinary S2O3 in otherwise healthy individ-
uals vary greatly and are sensitive to small fluctuations in atmos-
pheric H2S [47]. In animal studies where SO32, SO42 and
S2O32 have been measured simultaneously, H2S exposure
resulted in a greater elevation of SO32 and SO42 compared to
S2O32 in lung tissue [48]. Similarly, incubation of plasma, liver,
colonic or muscle tissue with H2S or one of its metabolites
methanethiol (see below) also leads to S2O32 and SO42 gener-
ation [49]. These findings strongly suggest that the metabolism of
H2S in vivo is complex and the reliability of S2O32 as an index of
endogenous H2S synthesis requires further attention.
Further cellular H2S removal processes also exist. For example,
in the cytosol, H2S also undergoes methylation in by thiol- 
S-methyltransferase (E.C. 2.1.1.9) to yield methanethiol (CH3S)
and dimethylsulfide (CH3SCH3) [49, 50]. An additional enzymatic
removal process which is potentially important in colonic tissue
involves rhodanese (thiosulfate : cyanide sulfurtransferase; E.C.
2.8.1.1) [51], an enzyme which catalyses the transfer of the sul-
fane sulfur atom from HS to a thiophilic acceptor (such as
cyanide) via an enzymic persulfide intermediate to form thio-
cyanate (SCN) and SO42. H2S can also be oxidized by activated
neutrophils to SO32– [52] suggesting H2S may represent an
important source of SO32 in vivo. Furthermore, H2S could also be
consumed by endogenous oxidant species in the vasculature such
as peroxynitrite [10], hypochlorite [23], superoxide [24, 25],
hydrogen peroxide [24, 25] and nitric oxide [26], mediators also
known to be produced in elevated amounts in various cardiovas-
cular pathologies.
H2S in the heart and vasculature
H2S is emerging as a novel and an important physiological
 mediator in the cardiovascular system. Much of our current
knowledge of the cardiovascular biology of H2S stems from 
the use of inhibitors of CSE such as D,L-propargylglycine (PAG),
-cyanoalanine and inhibitors of CBS such as aminooxyacetic
acid. These compounds apparently target the pyridoxal phosphate
binding site of these enzymes [53] and may not be entirely spe-
cific. It should also be noted that although intraperitoneal injection
of PAG results in its rapid accumulation into the blood (peak within
2 hrs), an as yet unidentified metabolite of PAG produced through
the D-amino acid oxidase pathway injures the renal proximal
tubule cells resulting in significant polyuria, proteinuria and gluco-
suria 5–6 hrs after injection [54]. As such, a possible diuretic
and/or other renal effects of this PAG metabolite (or PAG itself) 
in mediating the effects of PAG (and H2S) on systemic blood pres-
sure should be considered.
Nevertheless, in the present absence of wholly specific
inhibitors in this emerging field of research, studies using PAG
when combined with analytical techniques such as PCR, immuno-
histochemistry and Western blotting or more recently using ani-
mal knock-out models [55] have clearly shown CSE to be the more
important of the two known H2S synthesizing enzymes in the car-
diovascular system [55, 56], where its expression is induced by
pro-inflammatory mediators such as lipopolysaccharide and car-
rageenan but down-regulated during hypoxia, hypertension and
myocardial infarction (see Table 1). In sharp contrast, very little is
known about the role of H2S, CSE or CBS in human beings. To date
only, one study has shown CSE to be present in human vascular
tissue (internal mammary artery) [57] although it is known to be
expressed in human liver [58] and leucocytes [59]. Nevertheless,
the few emerging studies examining H2S levels in human blood
have clearly shown perturbed H2S synthesis in coronary heart dis-
ease [60] and myocardial infarction, where lower H2S levels have
been suggested to reflect disease severity (see Table 1).
Although experiments in man and animals have clearly shown
that removal of endogenous nitric oxide through inhibition of NOS
(i.e. with L-NAME) rapidly increases blood pressure, contrasting
effects of CSE inhibition (i.e. with PAG) have been reported. For
example, injection of PAG exerted little immediate effect on blood
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pressure in normotensive anaesthetized rats [61, 62] but
increased blood pressure after endotoxic [14] or haemorrhagic
shock [52] when administered either prophylactically or therapeu-
tically. This suggested CSE-derived H2S as a pathological media-
tor in blood pressure homeostasis. In sharp contrast, longer-term
injection of PAG in rats for 2–3 weeks significantly increased 
systolic blood pressure [63] suggesting the role of CSE was reg-
ulatory, rather than pathological. These disparities could either
reflect the manner in which PAG was administered or merely the
extent to which PAG is cell permeable in different animal models
systems and different animal strains. Although PAG reduces H2S
levels in the plasma of various animal models (see Table 1) and the
activity of CSE in isolated cells in vitro, it has been so far assumed
that PAG is freely cell permeable. However, to the best of our
knowledge, studies explicitly showing cellular uptake of PAG are
lacking. Nevertheless, by far the most compelling evidence for the
role of H2S in the vasculature is from very recent studies using
CSE single and double knock-out mice [55] where CSE/ and
lesser extent CSE/ mice had significantly higher systolic arterial
blood pressure then CSE/ mice. Furthermore, CSE/ mice
were substantially more sensitive to H2S-mediated vasodilatation
than wild-type mice [55].
Plasma or serum levels of H2S in rat, mouse and human adult
plasma vary between ~23 and 60 M (summarized in Table 1).
Within these reported plasma concentration ranges, H2S induces
the relaxation and transient blood pressure reduction in a variety
of vascular tissue such as rat aorta and portal vein [64, 65], rab-
bit corpus cavernosum [66] as well as perfused rat mesenteric
[67] and hepatic [68] vascular beds. H2S has been shown to be
produced in myocardial tissue by CSE in vitro and in vivo to pro-
tect against hypoxia-reperfusion injury, where it exerts a negative
inotropic effect and preserves left ventricular function by lowering
left ventricular systolic and end diastolic pressure and reducing
infarct size [25, 69–72]. The mechanism for the vasculoprotective
effects H2S (summarized in Table 2) may be mediated by a direct
stimulation of plasma membrane KATP channel-dependent vasore-
laxation resulting in increased vascular flow. Rodent aortic ring
preparations exposed to high concentrations of K ions show
markedly reduced vasorelaxant response to H2S and KATP channel
antagonists such as glibenclamide or 5-hydroxydecanoate (5HD)
effectively blocked H2S-mediated vasodilatation [65, 70, 71].
Patch clamp studies using isolated rat mesenteric [73] and aortic
[74] vascular smooth muscle cells exposed to H2S show
increased glibenclamide-inhibitable KATP-dependent current and
cellular hyperpolarization [75]. However, H2S-mediated opening of
KATP channels does not occur in isolated rat cardiomyocytes [76]
suggesting the effects of H2S on KATP may be cell specific.
Additional pathways for H2S-mediated vasodilation have also
been proposed. For example, H2S activates adenylate cylcase and
elevates cAMP in cultured neurons [30, 32] and isolated human
vascular smooth muscle (HVSM) cells [77], suggesting a
vasodilatory effect mediated through cAMP is also possible. On
the other hand, the activation of this cAMP pathway was not
observed in isolated rat cardiomyocytes where the inhibition of 
L-type Ca2 channels was proposed [76] or rat vascular endothelial
cells [78]. These findings further suggest cell and perhaps species
specific effects of H2S on vascular cells as have been observed
with nitric oxide.
H2S is further reported to stimulate charybdotoxin/apamin-sensi-
tive K channels in vascular endothelium [73, 75] although other
laboratories have not observed this [79]. Nevertheless, it is highly
likely that, as with nitric oxide the vascular endothelium represents
the major target for H2S [55, 73, 75, 79]. Consistent with this,
reduced CSE expression/activity and decreased H2S concentration
contributes to the pathophysiology of pulmonary hypertension in
rodents [80] whereas CBS deficiency leads to hyperhomo-
cyst(e)inemia, increased blood pressure and endothelial dysfunction
[81, 82]. Although CBS is not considered to be the vascular source
of H2S [55], tissue deficiencies in CBS are thought to manifest in the
vasculature as a consequence of homocysteine accumulation
(reviewed in [83, 84]). Homocysteine is directly toxic to vascular
endothelial cells (reviewed in [85, 86]) and induces apoptotic cell
death [87], up-regulates surface expression of intracellular adhesion
molecule (ICAM)-1 [88], augments monocyte adhesion [89] and
promotes interleukin (IL)-1 and tumour necrosis factor- forma-
tion [90] and interferes with vascular nitric oxide synthesis and
bioavailability [91–94]. Interestingly, homocysteine treatment of
Sprague-Dawley rats markedly increased plasma H2S levels via
increased expression and activity of CSE [34] and it is tempting to
speculate that this response by vascular cells to synthesize vasodila-
tory H2S in the presence of a detrimental vascular toxin was a pro-
tective and/or compensatory response to maintain vascular patency.
In rodents, CBS or CSE deficiency induced by genetic deletion
or chronic treatment with PAG results in a severe hypertension
and severe loss of endothelial function [55, 82]. Interestingly, a
close examination of the published literature clearly shows that
spontaneously hypertensive rats have lowered H2S concentrations
than rats from other species (i.e. WKY, Wistar, Sprague-Dawley)
(Table 1). Furthermore, rodent models of pulmonary and hypoxic
hypertension also show decreased plasma H2S levels. In each
case, the administration of the H2S donor, NaHS, reduced blood
pressure. Interestingly, children are reported to have higher
plasma levels of H2S than adults [95] and one study has shown
that plasma H2S concentrations are decreased with age in adults
over 50–80 years old [33]. Together with the observation that
H2S-mediated vasodilation is at least partly endothelium depend-
ent [65, 73–75, 79]; this suggests that there is a possible loss of
H2S synthesizing capacity or bio-availability over time that paral-
lels age-associated increases in blood pressure in man.
It is possible that part of the vasculoprotective effects may be
due to inhibition of platelet aggregation [96]. However, this is
unlikely since significant inhibition platelet aggregation by H2S
(~30 M) at physiologically relevant concentrations was only
observed with ADP and millimolar concentrations of NaHS were
required to inhibit platelet aggregation induced by other mediators
such as collagen, arachidonate and thrombin. It is further likely
that H2S removes toxic oxidants that are known to be detrimental
to endothelial function in the vasculature [11, 23–26]. An addi-
tional protective effect, consistent with a potential antioxidant role
of H2S, may be in limiting vascular protein modification such as
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Observation Example Comment References
Antioxidant activity Scavenging or removal of toxic radical and radi-
cal-derived intermediates (i.e. ONOO, HOCl, O2,
H2O2, nitric oxide) 
Cytoprotective effects observed in neuronal
cells but potent in vitro oxidant scavenging also
observed so it is possible the interaction with
H2S and these oxidants also occur in the vascu-
lature. Indeed, H2O2 / O2 ‘scavenging’ pre-
vented myocardial injury in vitro.
[11, 23–26] 
3-nitrotyrosine (a bio-marker for ONOO) and
MDA levels (a bio-marker for lipid peroxida-
tion) in rat heart were reduced in a model of
myocardial ischemia reperfusion 
[99]
Inhibition of oxidative modification to low-density
lipoprotein
Oxidation of low-density lipoprotein consid-
ered pro-atherogenic
[97] 
Inhibition of NADPH oxidase synthesis and O2
formation in human vascular smooth muscle cells
Down-regulation of NADPH oxidase expres-
sion. Possible involvement of cAMP and pro-
tein kinase A
[77]
NaHS induces glutathione (GSH) synthesis and
decreases plasma levels of oxidized glutathione
(GSSG).
Effects observed in neuronal cells. Increased
cysteine uptake and increased activity of 
-glutamylcysteine synthetase; GSH is an
effective extracellular and intracellular antioxi-
dant NaHS increased plasma total antioxidant
capacity 
[21, 22, 30, 114]
Effects on vascular cells Inhibition of vascular smooth muscle cell prolifer-
ation
Activation ERK and p21cip/WAF-mediated path-
way; observed in rat and human cells either
treated with NaHS or through over-expression
of CSE. 
[100, 102]
However, inhibition of ERK has also been
reported.
[101]
Induction vascular smooth muscle cell apoptosis Human artery smooth muscle cells. ERK and
p38 MAPK activation, up-regulation of
p21cip/wak1 and down-regulation of cyclin D1
expression. Caspase-mediated cell death.
[103, 104]
Induction of endothelial cell adhesion, migration
and proliferation 
AKT and PI-3K-dependent pathways [98–102]
Inhibition of myocardial apoptosis Rat model of myocardial ischemia-reperfusion
injury. NaHS-mediated inhibition of apoptosis
was abolished by the putative mitochondrial
KATP channel inhibitor 2-HD. JNK, p38 and 
NF-B-dependent pathways also activated.
[99]
Promotion of angiogenesis AKT pathway proposed. [78] [99]
NaHS inhibited adhesion molecule expression
(ICAM-1) in rat model of myocardial ischemia
reperfusion
Table 2 Summary of effects consistent with a protective role for H2S in the vasculature
Continued
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Observation Example Comment References
H2S required for cardio-
vascular health
Vasodilator effects Vasodilation via opening KATP channel in smooth
muscle and vascular endothelium; Induces relax-
ation and transient blood pressure reduction in
rat aorta, portal vein and mesenteric and hepatic
vascular beds; induces relaxation of rabbit corpus
cavernosum; induces relaxation in human internal
mammary artery.
H2S-mediated vasodilation was endothelium
dependent and inhibitable by glibenclamide or
5HD suggesting KATP-channel-dependent
effects
[57, 64–68,
74–76, 79]
Inhibition of angiotensin-converting enzyme activ-
ity of endothelial cells
If this reaction occurred in vivo it could poten-
tially lead to vasodilation in vivo since inhibi-
tion of angiotensin-converting enzyme would
decrease plasma levels of the angiontensin-II
and decrease the breakdown of bradykinin. 
[105]
Presumably the effect of H2S on angiotensin-
converting enzyme was due to H2S-interaction
with the active site Zn2 ions since exogenous
Zn2 prevented enzyme inhibition. However,
the effect could also be due to direct ‘scaveng-
ing’ effect of Zn2 ions on H2S as it is the
basis of the methylene blue assay
Activation of adenyl cyclase and cAMP-mediated
vasodilation
NaHS increased cAMP in human vascular
smooth muscle cells;
[77] 
NaHS also induces cAMP formation in cul-
tured neurons and macrophages suggesting
one additional mechanism for H2S-mediated
vasodilation is mediated through adenyl
cyclase / cAMP.
[30, 32]
However this effect was not observed in iso-
lated rat cardiomyocytes or rat vascular
endothelial cells highlighting potential cell-
 specific and species-dependent effects of H2S.
[75, 77]
Low plasma levels impli-
cated in cardiovascular
disease
Spontaneously hypertensive rats have lower
plasma H2S levels than normotensive WKY,
Wistar or Sprague-Dawley rats
Data consistent with H2S as a physiological
regulator of blood pressure
See Table 1 for
comparison of
levels between
different rat
strains
Low CSE expression, activity and H2S levels con-
tribute to the pathology of hypertension, coronary
heart disease, angina, hypoxia and ischemia-
reperfusion injury 
Data consistent with H2S as a physiological
regulator of blood pressure and cardiac func-
tion; low plasma H2S reflected severity of car-
diovascular disease. 
[15, 25, 33, 60,
61, 79, 95, 110,
113, 114] [55]
Low levels could suggest decreased H2S syn-
thesis or consumption by toxic intermediates
such as nitric oxide, ONOO, O2 HOCl or H2O2.
CSE/ mice have higher blood pressure than
CSE/ and CSE/ mice
Table 2 Continued
Continued
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Observation Example Comment References
Slow release H2S donor decrease systolic blood
pressure in spontaneously hypertensive rats but
not normotensive WKY rats
Effects of NaHS compared with a novel slow
releasing H2S donor; biphasic effects of H2S
[79]
Plasma H2S levels decline with increasing age. H2S-mediated vasodilation is endothelium
dependent. Age-dependent increase in blood
pressure and endothelial dysfunction are well
documented. Data consistent with H2S as a
physiological regulator of blood pressure. 
[33]
Interestingly, hypertensive children had lower
H2S than normotensive children.
Normotensive children have higher plasma
H2S than adults. 
[95]
Cardiovascular protective
effects of H2S
Protection against
myocardial ischemia-
reperfusion and myocar-
dial infarction injury
Preserves left ventricular contractility and reduces
infarct size 
Opening of mitochondrial KATP channels and
up-regulation of BCl2 protein to prevent mito-
chondrial permeability and release of pro-
death factors (i.e. cytochrome c) i.e. H2S is
cytoprotective. Inhibition of c-Fos signalling.
Inhibition of pro-inflammatory signalling (p38,
JNK and NF-B) 
[69–72, 99, 115]
Preservation of mitochondrial ultrastructure and
respiratory function during ischemia reperfusion 
H2S is a mediator in ischemic preconditioning H2S activated AKT, PKC· and PKC-dependent
signalling
[121]
Inhibition of platelet aggregation Concentrations of H2S within the physiological
range (~30 µM) prevented ADP-induced
platelet aggregation. However, mM concentra-
tions of H2S required to inhibit platelet aggre-
gation via other mediators. Plasma H2S
unlikely to reach mM concentrations.
[96]
Inhibition of L-type Ca2 channels in isolated rat
cardiomyocytes
NaHS inhibited electricity-stimulated intracellu-
lar Ca2 mobilization in a KATP-channel inde-
pendent manner. Potential to reduced myocar-
dial hypertrophy and inhibit cardiomyocyte
apoptosis. 
[76]
Table 2 Continued
inhibiting HOCl-mediated atherogenic modification of low-
density lipoprotein and apolipoprotein and inhibit myeloperox-
idase activity, presumably by interaction at the heme moiety of
myeloperoxidase [97].
Alternatively, the cytoprotecitve effects of H2S may be due to
the initiation of ‘protective cellular’ signalling pathways within car-
diac and vascular tissues. For example, H2S induces extracellular
regulated kinase (ERK) and protein kinase B (AKT) signalling path-
ways in cardiac tissue [78, 98, 99] and preserves mitochondrial
ultrastructure and respiratory chain function in vivo [72] possibly
via a mitochondrial pathway involving the preservation of Bcl-2
signalling and intriguingly, a mitochondrial KATP-channel-dependent
mechanism [99]. H2S is also reported to induce vascular angio-
genesis and induced neovascularization in mice in vivo as well as
promote proliferation, adhesion and migration in cultured endothelial
cells via AKT and phosphatidylinositol 3-kinase phosphorylation
J. Cell. Mol. Med. Vol 13, No 3, 2009
501© 2009 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
[78, 98]. Furthermore, H2S was recently shown to inhibit neoin-
tima formation after balloon injury in rat carotid artery in vivo by
inhibiting vascular smooth muscle cell proliferation [100, 101], an
effect also observed with HVSM cell proliferation in vitro by either
inducing or inhibiting [101] ERK and p21cip/WAF phosphorylation
[102]. Furthermore a pro-apoptotic effect of H2S on HVSM cells
has also been proposed, also mediated through ERK/p21cip/wak-1
[103] and p38 pathways involving caspase-3 activation [103, 104]
suggesting that the role of H2S in the vasculature is to activate the
endothelium and inhibit vascular smooth muscle cell function.
Indeed, as with nitric oxide mediated vasorelaxation, the vasodilata-
tory effects of H2S are endothelium dependent [65, 73–75, 79].
An additional effect of H2S may be due to the inhibition of
angiotensin-converting enzyme on the surface of vascular
endothelial cells [105] possibly resulting from an interaction
of H2S with the Zn2 moiety at the enzyme’s active site.
Should the corresponding reaction occur in vivo this would
result in vasodilation due to lowered circulating levels of the
vasoconstrictor angiotensin-II and consequently decrease the
breakdown of the vasodilator bradykinin. Since it is also likely
that H2S interacts with NOS3 and endothelial of release of
nitric oxide, this suggests that these gases may be recipro-
cally regulated (see below). Indeed, H2S appears to activate
adenylate cyclase/cAMP [30, 32, 77] signalling in certain cell
types (but not others [76, 78]) whereas nitric oxide mediated
effects are via guanylate cyclase/cGMP perhaps suggestive of
complementary or competing pathways for the control of 
vascular tone.
Although the bulk of these publications to date have sug-
gested that H2S is an endogenous vasodilator, concentrations of
H2S towards the lower end of that measured physiologically
have also shown that H2S induces endothelium-dependent
vasoconstriction in rat [65] and human arteries [57]. In non-
mammalian vertebrates, H2S induces vasorelaxation or vaso-
constriction (or both) [13, 106]. In isolated bovine pulmonary
arteries H2S causes tissue contraction whereas it induces a
complex contraction–relaxation–contraction response in rat
pulmonary arteries [106]. Indeed closer examination of the pio-
neering publications which examined the vasodilator effects of
H2S on isolated rat aortic rings clearly show that low concentra-
tions of H2S induce contraction [74, 75, 80]. Although this was
not stated in the text of these publications, these findings are
clearly visible in the published figures. We recently expanded
these early studies and showed that in phenylephrine pre-
contracted rat aortic ring preparations [65] and isolated human
internal mammary artery [57], low concentrations of H2S-
induced tissue contraction followed by relaxation. Both of these
effects were dependent on intact endothelial cells since
denuded tissue showed neither tissue contraction (at low H2S
concentrations) or relaxation (at higher H2S concentrations)
[65]. Furthermore we also showed that low concentrations of
H2S-induced endothelium-dependent vasoconstriction in vitro
and in anaesthetized rats this was inhibited by removal of
endogenous nitric oxide with L-NAME [65] again suggesting
molecular ‘cross-talk’ between H2S and nitric oxide.
Evidence for ‘cross-talk’ between nitric
oxide and H2S
H2S-induced vasorelaxation is only partially blocked by gliben-
clamide when used at a concentration of 10 M [57, 65, 73–75, 79],
which is an appropriate concentration for KATP specificity. This
implies the involvement of additional KATP-dependent mechanisms
for these vascular effects. Together with the studies highlighted
above, these findings strongly suggest the possibility of ‘cross-talk’
between vascular nitric oxide and H2S. However, the precise nature
of such an interaction has proved difficult to characterize accu-
rately. Recent studies in vascular tissue and cells from several
species have shown H2S either acts at the level of NOS, nitric oxide
influences CSE activity and that H2S (or species derived from it at
physiological pH) interact with vascular-derived nitric oxide and
vice versa with apparent formation of a ‘nitrosothiol’-like species. A
summary of the present evidence consistent with cross-talk
between H2S and nitric oxide is presented in Table 3.
The direct effects of H2S on NOS activity has been investigated
with mixed results and as appears common for the emerging area
of H2S biology, the mechanisms for these observations have not
been fully investigated. For example Kubo et al. [107, 108] showed
recombinant NOS1 (rat), NOS2 (mouse) and to a latter extent,
NOS3 (bovine) were inhibited by NaHS perhaps through 
interfering with tetrahydrobiopterin binding. Work by others 
[63, 109–111] subsequently showed that H2S inhibited NOS3 but
not NOS2 activity in isolated rat and mouse aortic rings [107] and
in human umbilical vein endothelial (HUVE) cells [109]. However,
the lack of effect of NOS2 is not surprising since NOS2 is an
inducible protein and was not induced in these experiments.
Nevertheless, further experiments showed that intraperitoneal
injection of NaHS into rats significantly reduced plasma
NO2/NO3 levels and suggested inhibition of NOS3 activity
[109]. However, in each of these studies, free nitric oxide, H2S or
S-nitrosothiols were not measured. It is therefore possible that the
lowered NO2/NO3 levels in plasma, as an index of nitric oxide,
reflected the consumption of nitric oxide by either the added H2S
gas, the added H2S donor (NaHS) or endogenously produced H2S
via L-cysteine/pyridoxal phosphate in these studies.
It is also possible that H2S exerts its effects on nitric oxide syn-
thesis via modulation of NOS substrate availability. For example in
a rat model of pulmonary hypertension, induced by abdominal
aorta-inferior cava vein shunt, L-arginine up-regulated CSE
expression and H2S synthesis in pulmonary artery smooth muscle
cells [111, 112]. However, in rat aortic tissue and HUVE cells H2S
gas or H2S generated via L-cysteine/pyridoxal decreased L-
 arginine uptake and NO2/NO3 formation through an apparently
KATP sensitive pathway [109], suggesting H2S could serve as a
negative regulator of nitric oxide synthesis.
The effects of nitric oxide donors on H2S synthesis have also
been investigated with species and tissue-dependent effects and
contradictory findings reported. For example, the nitric oxide
donor, sodium nitroprusside (SNP) up-regulates H2S production
in rat vascular tissues and brain by increasing the expression of
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Cardiovascular observation
Involvement in common cardiovascular pathology
Endogenous H2S and nitric oxide levels negatively correlate with blood pressure and cardiac function
Haemorrhagic and endotoxic shock induce elevated H2S and nitric oxide synthesis; prophylactic and therapeutic pharmacological inhibition of
CSE or NOS2 is protective
Inflammation and oedema are associated with elevated H2S and nitric oxide levels; inhibition of CSE or NOS decreases inflammation and swelling
Stimulatory effects of H2S on nitric oxide synthesis and nitric oxide mediated vasorelaxation
The nitric oxide donor sodium nitroprusside (SNP) enhanced CBS activity and H2S levels in vitro and increased H2S synthesis in rat aortic,
liver and ileum [63, 112]
The vasorelaxant effect of the nitric oxide donors SNP and SIN-1 were enhanced by incubating rat aortic tissue with NaHS [64]
L-NAME inhibited H2S-mediated vasorelaxation in rat aorta and the conversion of L-cysteine to H2S in rat aortic tissue. This effect was
enhanced by treatment with the nitric oxide donor SNP [73]
NaHS [64, 65] or slow release H2S donor GYY4137 [79] prevented and reversed L-NAME-mediated hypertension in rats
H2S potentiated expression of NOS2 following stimulation of cultured rat vascular muscle cells with interleukin (IL)-1
H2S inhibited nitric oxide generation in isolated aortic tissues and in vivo [109] H2S down-regulated NOS3 (eNOS) but not NOS2 (iNOS)
expression however, NOS2 was not induced [107, 108]
H2S, NaHS inhibited L-arginine uptake in human umbilical vein endothelial (HUVE) cells [109, 110]
L-cysteine / pyridoxdal phosphate inhibited L-arginine uptake in HUVE cells; inhibited by PAG [109, 110]
L-Arginine increased CSE mRNA expression in pulmonary vascular endothelial and smooth muscle cells [110] 
Nitric oxide donors up-regulated the expression and activity of CSE in vascular tissues and cultured aortic smooth muscle cells [74, 124]
Synergistic effect of nitric oxide and H2S on stonustoxin-induced relaxation of isolated rat aorta [123]
Synergistic effect of nitric oxide and H2S on rat pulmonary artery relaxation [64]
H2S-mediated ischemic after conditioning involved activation of NOS3 [121]
Inhibitory effects of H2S on nitric oxide synthesis and nitric oxide mediated vasorelaxation
NaHS inhibited recombinant NOS1 (nNOS) and NOS3 (eNOS) activity through interaction with BH4 and NOS2 through unknown 
mechanisms [107–109]
L-NAME inhibited CSE expression and H2S synthesis in thoracic artery and superior mesenteric artery in rats [80]
Nitric oxide dependent relaxation of rat aortic rings through either nitric oxide donors (SNP, SNAP or SIN-1) or nitric oxide dependent (acetyl-
choline, histamine) but not nitric oxide independent (i.e. isoprenaline) mediators was inhibited by exogenous (H2S gas, NaHS) and endogenous
(L-cysteine/pyridoxal phosphate) H2S; an effect reversed by PAG [65]
L-NAME inhibited H2S-induced increase in mean arterial blood pressure in anaesthetized rats [65]
H2S inhibited vasorelaxation of isolated human internal mammary artery; induced by nitric oxide dependent mechanisms (i.e. acetylcholine) [57]
PAG inhibited SNP-mediated vasorelaxation of isolated rat aorta [114]
Other evidence of RNS-H2S interaction
Scavenging’ of ONOO; inhibition of ONOO-mediated cell death, intracellular protein nitration and tyrosine nitration in vitro [11]
Inhibition of tyrosine nitration in vivo in animal model of myocardial ischemia reperfusion [99]
Several nitric oxide donors react with NaHS in vitro to form a species resembling an inert ‘nitrosothiol’ [11, 26, 57, 65]
H2S-dependent nitrosothiol formation during lipopolysaccharide-induced septic shock in the rat [26]
NaHS-mediated decrease of O2 formation in human vascular smooth muscle cells was inhibited by the nitric oxide donor spermine 
NONOate [77]
Table 3 Evidence consistent with nitric oxide–H2S cross-talk in the cardiovascular system
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CSE or CBS [110–112] suggesting a possible interaction of these
gases at the expression of their synthesizing enzymes. In rat aor-
tic tissue, the vasorelaxant effect of SNP was enhanced in the
presence of NaHS. At the level of vascular smooth muscle cells,
H2S has been reported to either enhance [63] or to attenuate 
[65, 75] the relaxant effect of nitric oxide in the rat aorta and
human internal mammary artery [57]. Furthermore, NaHS-medi-
ated inhibition of O2 production in HVSM was attenuated by
nitric oxide (supplied as spermine NONOate) [64]. However, it is
also possible that O2 was consumed by nitric oxide (forming
ONOO) or ‘scavenged’ by H2S [23–26].
Evidence for the formation of a novel 
intermediate between nitric oxide 
and H2S at physiological pH
Given the reportedly high concentrations of H2S in the vasculature
(Table 1) and the extensive tyrosine nitration (as a bio-marker for
ONOO) and NO2/NO3 (as bio-markers for nitric oxide)
observed in human tissues and fluids, (especially during pathol-
ogy [4–7]), the reaction between H2S and ONOO is plausible.
Indeed, H2S was recently shown to react with ONOO (or species
derived from it at physiological pH) to inhibit nitrosative stress,
cellular 3-nitrotyrosine formation and accompanying cell death
[11]. However, since the half life of ONOO at pH 7.4 and 37	C is
1 sec. [4–6], a much more plausible reaction is between nitric
oxide (or intermediates derived from it) with H2S, especially since
plasma levels of NO2 (indicative of nitric oxide synthesis) are
reported to reach high concentrations during chronic inflamma-
tion, oedema and sepsis; the precise conditions in which H2S syn-
thesis is stimulated. Indeed, spectrophotometric, amperometric
and electron paramagnetic resonance spectroscopy have recently
shown that H2S (or intermediates derived from it at physiological
pH) also reacts with nitric oxide (or derived species at physiolog-
ical pH) to form a novel nitrosothiol-like compound(s) [26].
Further, incubation of RAW264.7 cells with nitric oxide donors
(but not NaHS) resulted in cGMP accumulation but in sharp con-
trast, pre-mixing the nitric oxide donor SNP with NaHS did not
result in cGMP formation unless Cu2 was added to release nitric
oxide. This finding suggests that the ‘nitrosothiol’ did not increase
cGMP levels itself but only after release of nitric oxide [26] and
that this ‘nitrosothiol’ molecule was a relatively inert under these
conditions. It is therefore tempting to speculate that the ‘nitrosoth-
iol’-like molecule may act as a sink for regulating nitric oxide
and/or H2S bioavailability.
The H2S–nitric oxide interaction has also been investigated ex
vivo and in vivo using exogenous and endogenously produced
H2S and nitric oxide. In rat aortic ring preparations the addition
several nitric oxide donors (SNP, SIN-1, SNAP) to phenylephirine
pre-contracted rat aortic rings resulted in substantial relaxation
but the subsequent addition of NaHS or authentic H2S gas
resulted in marked inhibition or reversal of nitric oxide donor-
mediated relaxation [65]. However, pre-mixing nitric oxide
donors with NaHS did not result in aortic ring relaxation unless
Cu2 was added to release nitric oxide from H2S-nitric oxide [52]
again suggesting that the ‘nitrosothiol’-like molecule formed
through the interaction of nitric oxide with H2S at physiological
pH was inert. In addition, in isolated rat aortic rings [65] and
human internal mammary artery [57], nitric oxide dependent 
(i.e. using histamine or acetylcholine) but not nitric oxide inde-
pendent relaxation (i.e. using isoprenaline) was substantially
inhibited by low concentrations of NaHS or H2S gas and this
effect removed or reversed by the addition of Cu2 [65]. Nitric
oxide dependent relaxation was also inhibited by the addition of
L-cysteine/pyridoxal phosphate (as CSE substrate/co-factor), an
effect reversed by the CSE inhibitor PAG [65]. Furthermore, we
also showed that in liver homogenates from LPS-treated rats,
‘nitrosothiol’ formation was enhanced after the addition of L-
 cysteine/pyridoxidal phosphate but inhibited by inclusion of PAG
in the incubate [26]. These results suggest that H2S and nitric
oxide or species derived from them at physiological pH, reacted
together to form a molecule (presumably a nitrosothiol) which
exhibited little or no vasorelaxant activity either in vitro or in vivo.
Unfortunately, at present the precise identity, molecular structure
and physiological properties of this nitrosothiol-like species are
currently unknown.
Concluding remarks
The precise role of H2S under physiological and/or pathophysiolog-
ical conditions remains unclear. The molecular interaction between
NOS–CSE, nitric oxide–CSE, H2S–NOS and nitric oxide–H2S are ill-
defined and require further attention. However, from the studies
outlined above, it is likely that the physiological role of H2S might
be to suppress the vasodilator effect of nitric oxide through two
distinct mechanisms; inhibition of NOS3 and ‘scavenging’ of nitric
oxide resulting in the enhancement of vascular contractility.
Conversely, under pathophysiological conditions whereby nitric
oxide and H2S synthesis are greatly increased (i.e. sepsis and
shock) the vasculoprotective action of H2S and H2S-mediated nitric
oxide ‘quenching’ are lost resulting in excessive and pathological
loss of vascular tone. The isolation and molecular identification of
the nitrosothiol-like species derived from H2S and nitric oxide will
greatly facilitate the unravelling of the complex interaction between
these gases and could address the varied and contradictory reports
on the physiology and pathophysiology of H2S and nitric oxide.
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